Retatrutide, a novel dual activator of the GLP-1 receptor and glucose-dependent released polypeptide (GIP) binding site , is showing promising outcomes in initial clinical studies. Ongoing research https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/